New Vice Presidents are Mr. John Lechleiter of Lilly and Mr. Masafumi Nogimori of Astellas
The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is pleased to announce that Mr. David Brennan, Chief Executive Officer of AstraZeneca has been elected IFPMA President. Mr. Brennan succeeds outgoing IFPMA President Mr. Haruo Naito, President and CEO of Eisai Co., Ltd. Mr. John Lechleiter, who is Chairman, President and CEO of Eli Lilly and Company, and Mr. Masafumi Nogimori, President and CEO of Astellas Pharma Inc., have been elected as Vice Presidents. The new President and Vice Presidents take office today and will serve for two years.
Mr. Brennan outlined his objectives for his term as President, which include building on existing IFPMA efforts to engage openly with partners in addressing pressing global health challenges, including non-communicable diseases, diseases of the developing world and anti-microbial resistance. Mr. Brennan said, “I would like to pay tribute to Mr. Naito, for the energy and commitment he has brought to his Presidency. As the first Japanese President of the IFPMA, he has brought a new perspective to our work and underlined the increasing globalization of our industry. Mr. Naito has led from the front, personally helping to develop and strengthen relationships with key external partners, particularly in Geneva and I want to build on the success of his Presidency.”
“Looking to the future, our industry needs to rebuild trust and do a better job of showing the public that we play a crucial role in addressing healthcare challenges, in all parts of the world. Increasing the levels of transparency is one of the best ways to build relationships and understanding, and I will help the IFPMA to continue its work in this area.”
“If there is a theme I want to underline during my presidency, it is that of the ‟shared commitment„. It is the sharing of the challenge that is so important.” Mr. Brennan concluded: “It is the collaborative effort that will really make the difference.”
Washington DC, 10 November 2010
